Patients receiving hormone therapy as part of their gender transition treatment have an elevated risk of cardiovascular diseases (CVD), including heart attacks, strokes and blood clotting, researchers say. Researchers determined and compared the incidence of CVD cases in the transgender population with that reported in the general population. The study showed that transwomen individuals, assigned male sex at birth but with female gender identity, receiving hormones as part of their transition had more than twice as many strokes as women and nearly twice as many strokes as men. In addition, there were five times as many blood clotting among transwomen than women and 4.5 times more than men. Heart attacks occurred at more than twice the rate among transwomen than women. On the other hand, transmen those assigned female sex at birth but had male gender identity and received hormones had a more than three fold rise in heart attack risk compared with women, said the study, published in the journal, Circulation. "In the light of our results, we urge both physicians and transgender individuals to be aware of this increased cardiovascular risk," said Nienke Nota, researcher at the Amsterdam University Medical Center in the Netherlands. "It may be helpful to reduce the risk factors by stopping smoking, exercising, eating a healthy diet and losing weight, if needed before starting therapy, and clinicians should continue to evaluate patients on an ongoing basis thereafter," suggested Nota. For the study, the researchers included 3,875 individuals who had received hormone treatment 2,517 transgender women received estrogen, with or without androgen suppressors, and 1,358 transgender men received testosterone as part of their transition.
IBM Watson Health and the Broad Institute of MIT and Harvard are expanding their partnership to help clinicians better predict the possibility of serious cardiovascular diseases. By working with genomics, clinical data and AI, IBM and the Broad Institute hope this three year project will help provide doctors with tools to tap into the potential of genomics data, and better understand the intrinsic possibility an individual has for a certain disease. Equipped with this knowledge, health professionals can potentially intervene and help to reduce this risk.This initiative will incorporate population based and hospital based biobank data, genomic information, and electronic health records to build upon and expand the predictive power of polygenic scoring, otherwise known as genetic risk scoring. IBM and the Broad Institute are aiming to build algorithms that can pinpoint and learn from trends in these data points, and then indicate a potential predisposition to certain health conditions. The project will also plan to make insights and tools widely available to the research community, including methods to calculate an individual 's risk of developing common diseases based on millions of variants in the genome.
Chance of rain: 0% Wind: NW at 5mph
The US cancer death rate has steadily dropped since 1991, with a total decline of 27 percent over 25 years, researchers reported yesterday in CA: A Cancer Journal for Clinicians. The deaths from cancer for every 100,000 people dropped from a peak of 215 in 1991 to 156 in 2016. Advances in cancer treatment and detection as well as a decrease in smoking have primarily driven the decrease, according to the authors.Although cancer was still the second leading killer in 2016, the study revealed a decline in deaths from the four major types of cancer: lung, breast, prostate, and colorectal. Lung cancer is the most deadly, but with fewer people smoking, the death rate among men has fallen by almost 50 percent since 1991, reports The Associated Press.
IBM Research has created tiny fingernail sensors designed to help clinicians detect and monitor disease progression via AI analysis of grip strength. Learn more: ibm.biz/Bd2XVe
The report in the journal Radiology suggested that sex specific guidelines may be needed to guard against head injuries in football, or soccer as it is widely called in the United States. "Researchers and clinicians have long noticed that women fare worse following head injury than men, but some have said that 's only because women are more willing to report symptoms, " said lead author Michael Lipton, professor of radiology, psychiatry and behavioral sciences at Albert Einstein College of Medicine.
Despite these achievements the majority of patients still succumb to their disease. For this reason, researchers and clinicians are continually striving to find new ways to develop the diagnosis and treatment of cancer for improved cancer prevention and cure.Cancer diagnosis can be considered as the tip of an iceberg and the underlying events that lead to the development of cancer are complex and involve a multistep process of malignant progression of cancer cells and immune recognition, as well as elimination of the transformed cells by our own immune system1 (Fig. 1). Cancers that have managed to grow under immune surveillance have undergone a process called immuno editing where variants of the tumour cells gain properties to survive immune attack. During this phase, a multitude of tumour intrinsic factors enable the cells to avoid immune recognition and several tumour extrinsic mechanisms promote the formation of an immunosuppressive tumour micro environment that leads to improper activation of tumour killing T cells and ultimately outgrowth of the tumour.
The collaboration will have Guerbet and IBM Watson Health co develop clinical decision support solutions including Watson Imaging Care Advisor for Liver, a diagnostic support tool that will utilize AI to automate the detection, staging, tracking, monitoring, therapy prediction and response of primary and second liver cancer for clinicians, according to a Guerbet press release published July 10. Imaging is a critical area of healthcare where we believe artificial intelligence can be used to expand the physician s view so they can be more informed in their diagnostic and treatment decisions for their patients," said Anne Le Grand, vice president of imaging at IBM Watson Health.
Watson Imaging Care Advisor for Liver is the collaboration s first product, a clinical decision support solution designed to use AI to automate everything from the detection to the recommended treatment of primary and secondary liver caners. This will be the first of a family of decision support tools that uses imaging analytics to help radiologists make important clinical decisions. Liver cancer is a growing health concern globally, and the use of augmented intelligence by medical imaging is well positioned to help address it, Yves L'Epine, Guerbet's CEO, said in a prepared statement. We are proud to work with IBM Watson Health to develop a solution dedicated to liver disease, which could help make it possible for clinicians to make more informed characterizations of tissue without recourse to biopsy.
The study, which is sponsored by the National Cancer Institute, National Institutes of Health and ECOG ACRIN Cancer Research Group, is published in The New England Study Of Medicine. Research started in 2006 and involves 10,273 breast cancer patients. Researchers examined whether endocrine therapy, which lowers estrogen levels, could be as effective as chemotherapy in treating breast cancer. Although hormone therapy has some potential side effects, it isn t nearly as invasive as chemotherapy drugs, which often have unpleasant side effects. The study found that 70 percent of women with breast cancer don't benefit from chemotherapy, and the National Cancer Institute says the findings quot;will help inform treatment decisions for many women with early stage breast cancer. quot;Per the study's findings, the five year survival rates between women who had chemotherapy and women who just had hormone therapy were both around 98 percent. While chemotherapy has been proven to be effective, it may not be the best option for every breast cancer patient. The Susan G. Komen Foundation says chemotherapy treatment is almost always administered intravenously or through a port to get the drugs into your bloodstream, and it takes several hours and may need to take place multiple times a week. Hormone therapy is either injected into the buttocks or taken orally, and it can be spread out and taken every two weeks. Researchers were able to determine which kind of breast cancer tumors would respond to hormone therapy through a test that analyzes 21 genes in breast cancer tissue. If the test is performed on early stage breast cancer patients, doctors have a better idea of how to treat patients. quot;The new results from TAILORx give clinicians high quality data to inform personalized treatment recommendations for women, quot; said lead author Joseph A. Sparano, M.D., associate director for clinical research at the Albert Einstein Cancer Center and Montefiore Health System in New York City and vice chair of the ECOG ACRIN Cancer Research Group.
Apollo Hospitals will build on its long legacy of clinical excellence with dedicated cancer care hospitals in India by implementing Watson for Oncology and Watson for Genomics across ten of its 64 hospitals. Watson for Oncology will be available at the Apollo Chennai and Delhi hospital from April 2018, followed by Hyderabad, Mumbai, Kolkata, Ahmedabad, Bhubaneshwar and Madurai over the next few months. Watson for Genomics will become available across the same locations in the following months. The Watson for Oncology and Watson for Genomics solutions will help oncologists at Apollo surface relevant data to bridge disparate sources of information and identify treatments that are personalized to each unique patient. Apollo Hospitals has been dedicated to providing patients with best in class cancer care for more than two decades now. Our collaboration with IBM is a reinforcement of our commitment to clinical excellence, said Preetha Reddy, Vice Chairperson of the Apollo Hospitals Group. Each person s cancer journey is unique and hence each patient s treatment plan must be unique too. IBM Watson for Oncology and Genomics will help the clinicians and oncologists at Apollo Hospitals augment their own expertise to deliver an unparalleled and personalized patient care across our hospitals.
;This collaboration will accelerate the pace of innovation to define the next generation of healthcare and wearables,; he added. The companies will also look to help better manage chronic conditions like diabetes and hypertension by using services such as Fitbit;s recently acquired ;Twine Health;. Using Google;s Cloud Healthcare API, ;Twine; can make it easier for clinicians and patients to collaborate on care, helping lead to better health outcomes and positive returns for employers, health plans and hospitals. "At Google, our vision is to transform the way health information is organised and made useful. By enabling Fitbit to connect and manage key health and fitness data using our Google Cloud Healthcare API, we are getting one step closer to this goal, " said Gregory Moore Vice President, Healthcare, Google Cloud. "Together, we have the opportunity to deliver up to date information to providers, enhancing their ability to follow and manage the health of their patients and guide their treatment, " he added.
The study, published on Thursday in the journal Cell, revealed new possibilities for novel immune based cancer therapeutics. It provided a push for clinicians to obtain and utilize comprehensive genomic information to enroll their patients into specialized "basket" or "umbrella" clinical trials."The Cancer Genome Atlas (TCGA)," funded by the National Institutes of Health, completed the genetic sequencing and analyses of about 10,000 tumors from patients spanning 33 types of cancer, and focused on identifying similarities between cancers based on changes in their genes, and the way their genes are expressed.
By analyzing parent provided information and videos of a child s natural behavior, the company s app uses machine learning to provide an assessment of whether that child is developing at the right pace, as well as to evaluate their behavioral health. The clinically validated app can identify autism among children as young as 18 months, according to Cognoa, and so far has been used by hundreds of thousands of families. Today, there is a profound, unmet need for earlier and more accurate diagnoses of behavioral health conditions which we know can create life changing results for children and their families, Cognoa CEO Brent Vaughan said in a statement. We are very encouraged by this FDA determination of Cognoa s AI based software as a medical device for diagnosis. Cognoa is committed to conducting additional clinical studies and working with both the FDA and clinicians to further validate both our diagnostic software as well as integrated digital therapeutics that will dramatically improve the standard of care for physicians, children, and their families."
In the Arthritis Care amp; Research study, investigators used a modeling approach incorporating primary and secondary data sources to project supply and demand of the rheumatology workforce including physicians, nurse practitioners, and physician assistants who diagnose and treat conditions including osteoarthritis, gout, rheumatoid arthritis, lupus, vasculitis, and other autoimmune diseases through 2030.The 2015 adult workforce was estimated to be 6013 providers (5415 clinical full time equivalent FTE providers). Estimating the clinical FTE of rheumatology providers is important to better reflect rheumatology providers working full time seeing patients versus other rheumatology providers who may work as part time clinicians in private practice or in an academic rheumatology teaching practice. Clinical FTE describes the percentage of work effort devoted to clinical care to reflect a more realistic picture of patient access to care (e.g., two providers each caring for patients 50% of the time would together equate to 1.0 total clinical FTE). By 2030, the supply of rheumatology clinical providers is projected to fall to 4882 providers or 4051 clinical FTE, and demand is projected to exceed supply by 4133 clinical FTE.
The study published in the journal Arthritis Care amp; Research revealed that this inflammation could trigger COPD the umbrella term for diseases from emphysema to acute bronchitis which can cause wheezing and breathlessness. Rheumatoid arthritis sufferers have a 47 percent greater risk of the lung condition, while women with the condition see their danger rise by 61 percent, noted the researchers. For the study about 25,000 people with arthritis were monitored for over a decade. The findings revealed that along with the joints, the inflammation caused due to rheumatoid arthritis can also trigger lung diseases.The researchers believe that the findings could prove to be an important material for the ongoing research on COPD. it has only recently been recognized that inflammation plays a role in the development of COPD, and clinicians treating people with rheumatoid arthritis are not aware that their patients are at increased risk of developing COPD.
The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson s Research (MJFF), found that people with Parkinson s who injected themselves each week with exenatide for one year performed better in movement (motor) tests than those who injected a placebo.Also read: more news stories from the Michael J. Fox Foundation This is a very promising finding, as the drug holds potential to affect the course of the disease itself, and not merely the symptoms, said the study s senior author, Professor Tom Foltynie (UCL Institute of Neurology). With existing treatments, we can relieve most of the symptoms for some years, but the disease continues to worsen. The researchers followed 60 people with Parkinson s disease at the National Hospital for Neurology and Neurosurgery (NHNN) as they used either a once weekly injection of exenatide for 48 weeks, or a placebo, in addition to their regular medications.They found that people who used exenatide had better motor function at 48 weeks when they came off the treatment, which persisted after the 12 week follow up. Those who had injected the placebo showed a decline in their motor scores at both the 48 and 60 week tests. The advantage of 4 points, on a 132 point scale of measures such as tremors, agility and speech, was statistically significant.The participants did not report noticeable improvements in their symptoms during the trial period beyond what their standard medication already did for them. They were tested while temporarily off all medication, to determine how the disease itself was progressing. The research did not determine conclusively whether the drug was modifying the disease itself, so the next stage in the research will investigate that more fully.Parkinson s disease affects 1 in 500 people and is the second most common neurodegenerative disease worldwide. Symptoms typically don t become apparent until over 70% of the brain s dopamine producing cells have been affected. The condition results in muscle stiffness, slowness of movement, tremors, sleep disturbance, chronic fatigue and an impaired quality of life.Learn more: Parkinson's Disease researchThe saliva of the Gila monster lizard provided the inspiration for the development of exenatide, which has been used since 2005 to treat Type 2 diabetes. It activates receptors for the GLP 1 hormone in the pancreas to stimulate insulin release. GLP 1 receptors are also found in the brain, and prior research has shown that activating them can boost the function of dopamine connections, act as an anti inflammatory, improve energy production, and switch on cell survival signals. Further research by a team led by Professor Foltynie will seek to clarify how exenatide works for people with Parkinson s disease.Prior evidence in animal models demonstrated that exenatide improved motor performance. Another study also found early evidence that it could be a disease modifying agent for Parkinson s, but it was an open label trial, so this latest study strengthens the existing evidence as the first randomised, placebo controlled trial of the drug for Parkinson s patients. This is the strongest evidence we have so far that a drug could do more than provide symptom relief for Parkinson s disease, said Professor Foltynie. Using approved therapies for one condition to treat another, or drug repurposing, offers new avenues to speed Parkinson s therapeutic development, said Dr Brian Fiske, senior vice president of research programs at MJFF. The results from the exenatide studies justify continued testing, but clinicians and patients are urged not to add exenatide to their regimens until more is known about their safety and impact on Parkinson s. While we are optimistic about the results of our trial, there is more investigation to be done, and it will be a number of years before a new treatment could be approved and ready for use. We also hope to learn why exenatide appears to work better for some patients than for others, said the study s first author, Dr Dilan Athauda (UCL Institute of Neurology).This article has been republished from materials provided by UCL. Note: material may have been edited for length and content. For further information, please contact the cited source. A Blood based Screening Test for Alzheimer's
New Palestine High School wrestling head coach Alex Johns discovered this quickly as he began seeking out off season opportunities for his team.Shortly after the IHSAA state finals this past February, Johns researched several four day wrestling camps in Ohio, Missouri, Illinois and throughout the Midwest. Each looked promising and carried substantial clout with multiple high caliber clinicians, but they often came with a hefty $400 price tag.
Fortive Corp (FTV) formed double top with $65.89 target or 3.00% above today;s $63.97 share price. Fortive Corp (FTV) has $22.08B valuation. About 82,925 shares traded. Fortive Corp (NYSE:FTV) has 0.00% since June 23, 2016 and is . It has underperformed by 16.70% the S #038;P500.CareDx, Inc. is a molecular diagnostics company. The company has market cap of $23.78 million. The Firm is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. It currently has negative earnings. The Company 's commercialized testing solution, the AlloMap heart transplant molecular test , is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate severe acute cellular rejection.
Currently, clinicians can't diagnose autism until toddlers that are about 2, when the first behavioral and language symptoms of the developmental disorder become noticeable. Scientists are developing more sophisticated screening tests that rely on brain imaging techniques or eye tracking technologies that monitor an infant's gaze to pick up early autistic signs still there is no reliable way to diagnose the condition in younger infants.The director of Eunice Kennedy Shriver National Institute of Child Health and Human Development in the US, Diana Bianchi and NIH funded investigators at the University of North Carolina at Chapel Hill and Washington University School of Medicine in St. Louis used specific magnetic resonance imaging procedure to determine 82 percent of the newborns, who would go on to have autism (9 out of 11) and it correctly identified all of the children, who did not develop autism by using functional connectivity magnetic resonance imaging (fcMRI).